Acquisitions

Pharmaceuticals Mergers and Acquisitions Gene Editing Data Privacy Company Sales Corporate Strategy Mergers Curevac Corporate Transactions Gilead Sciences Genmab Investment Johnson & Johnson Eli Lilly

11 ARTICLES

3mo ago

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

The all-cash $77-per-share tender offer is intended to add FB102, a first-in-class anti-CD122 antibody, to broaden argenx’s immunology pipeline beyond Vyvgart.

8 ARTICLES

9mo ago

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

8 ARTICLES

last yr.

Sanofi Signs $1.15 Billion Deal to Acquire Vicebio’s Molecular Clamp Respiratory Vaccine Platform

9 ARTICLES

last yr.

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Acquisitions

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform

Sanofi Signs $1.15 Billion Deal to Acquire Vicebio’s Molecular Clamp Respiratory Vaccine Platform

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion